Sign In
Buy DXCM
$82.66
-4.28 (-4.92%)
At Close: Aug 05, 2026
Glucose monitor maker DexCom's stock soars after big earnings beat, raised revenue outlook as real-time monitoring awareness grows
04:48pm, Thursday, 26'th Oct 2023
Shares of DexCom Inc. DXCM, -3.86% shot up 15.3% to pace the S&P 500's SPX, -1.18% after-hours gainers on Thursday, after of maker of glucose monitoring systems reported third-quarter profit that beat
Dexcom lifts 2023 revenue view on strong demand for diabetes devices
04:42pm, Thursday, 26'th Oct 2023
Medical device maker Dexcom on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more th
2 Best Healthcare Stocks to Buy Right Now
09:15am, Thursday, 26'th Oct 2023
The stock market may be volatile, but investors don't have to wait on the sidelines. Vertex Pharmaceuticals is forging its own path in the rare disease drug market.
DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?
09:48am, Wednesday, 25'th Oct 2023
DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.
The 7 Best Nasdaq Stocks To Buy Now: October 2023
09:15am, Thursday, 19'th Oct 2023
Nasdaq stocks generally equate to higher-growth, technology-dominated firms in the eyes of most investors. The index is generally more rate-sensitive than leading indexes like the Dow and the S&P 500.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
08:16am, Thursday, 19'th Oct 2023
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.
Can DexCom (DXCM) Keep the Earnings Surprise Streak Alive?
01:32pm, Wednesday, 18'th Oct 2023
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Healthcare Stocks Near Their 52-Week Lows That Could Double in Value
09:53am, Wednesday, 18'th Oct 2023
DexCom is a big name in diabetes care, and investors may be overly bearish on the stock. InMode recently downgraded its guidance as rising interest rates impact its sales activity.
Is the Ozempic-Driven DexCom Selloff Overdone?
06:30am, Wednesday, 18'th Oct 2023
Plenty of businesses, such as PepsiCo Inc. NYSE: PEP and Walmart Inc. NYSE: WMT, have been under the microscope on fears of potential earnings decreases due to growing use of products like Novo Nordis
3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits
05:06am, Wednesday, 18'th Oct 2023
When stock-market volatility picks up, investors tend to gravitate to outperforming companies that have enacted stock splits. Nine high-profile companies have conducted forward-stock splits since the
Why the Market Dipped But DexCom (DXCM) Gained Today
07:33pm, Tuesday, 17'th Oct 2023
The latest trading day saw DexCom (DXCM) settling at $80.49, representing a +1.95% change from its previous close.
MedTech Earnings in the Age of Ozempic May Not Be That Bad
02:01pm, Tuesday, 17'th Oct 2023
September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
Why DexCom Stock Rallied on Monday
03:15pm, Monday, 16'th Oct 2023
The dramatic weight loss resulting from a new breed of diabetes medication has weighed on DexCom stock. As with all things, however, the devil is in the details.
What other industries could weight loss drugs disrupt?
07:10pm, Wednesday, 11'th Oct 2023
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
A Bull Market Is Coming: 2 Magnificent Stock-Split Growth Stocks That Could Soar 40% and 51%, According to Wall Street
07:00am, Sunday, 08'th Oct 2023
While stocks are taking a breather from their recent run, a bull market is on the horizon. Investor interest in stock-split stocks continues, as these stocks have historically generated strong gains o
